CN104814948A - 一种降血脂胶囊 - Google Patents
一种降血脂胶囊 Download PDFInfo
- Publication number
- CN104814948A CN104814948A CN201510039883.1A CN201510039883A CN104814948A CN 104814948 A CN104814948 A CN 104814948A CN 201510039883 A CN201510039883 A CN 201510039883A CN 104814948 A CN104814948 A CN 104814948A
- Authority
- CN
- China
- Prior art keywords
- blood fat
- acid
- alpha
- blood
- linolenic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 36
- 239000002775 capsule Substances 0.000 title claims abstract description 18
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 42
- 235000019197 fats Nutrition 0.000 claims abstract description 26
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 21
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 21
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005642 Oleic acid Substances 0.000 claims abstract description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 7
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 7
- 235000004347 Perilla Nutrition 0.000 claims description 11
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 8
- 229960004232 linoleic acid Drugs 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 150000003180 prostaglandins Chemical class 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- 235000004626 essential fatty acids Nutrition 0.000 abstract description 2
- 210000002216 heart Anatomy 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 2
- 235000021313 oleic acid Nutrition 0.000 abstract 2
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 235000004348 Perilla frutescens Nutrition 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 229960002969 oleic acid Drugs 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000003516 hyperlipidaemic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000735480 Istiophorus Species 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011930 active peptic ulcer disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- -1 furan alditol Chemical class 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种降血脂胶囊，所述胶囊包含α-亚麻酸、亚油酸和油酸；所述α-亚麻酸与亚油酸的质量比为4.377±0.1；所述α-亚麻酸与油酸的质量比为：4.096±0.1。本发明以紫苏油为主要原料，富含多种对人体有益的营养物质，主要成分：α-亚麻酸是ω-3系必需脂肪酸的母体，天然含量高达62.5%以上，α-亚麻酸与亚油酸含量比例高达4:1以上，科学合理，营养全面，有效避免药物的多种副作用和不足；能够降低低密度脂蛋白在血液中含量，使大脑及心脏得到有效保护，其通过前列腺素的降脂途径具有全项降脂作用。
Description
技术领域
本发明属于生物医药技术领域，具体涉及一种降血脂胶囊。
背景技术
据2000年全国心脑血管疾病学会透露，目前我国心脑血管疾病患者超过1.8亿人,而且患病人群平均年龄由50岁以上向30-40岁转移。患病率、发病率、致残率、死亡率不断上升，每年死于心脑血管疾病患者达300万人以上。心脑血管疾病已成为人类健康的“第一杀手”，占总死亡率的50%以上，平均每10秒死亡1人。而导致心脑血管疾病的一个重要原因，就是高血脂症。
大量研究资料表明，高血脂症是脑卒中、冠心病、心肌梗死、猝死的危险因素。此外，高血脂症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。高血脂症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症。
根据临床统计：高血压患者死于脑溢血占41%，冠心病占42%，心力衰竭占28%、肾衰竭占12%。当然，世界卫生组织也指出：只要采取预防措施就能减少一半的以上情况造成的死亡。所以必须高度重视高血脂的危害，积极的预防和治疗。
针对上述情况，现有技术中对其进行预防和治疗的方法存在很多缺点：
例如以阿司匹林为代表的降压药物存在以下不足，
①.阿司匹林的主要作用机制是抑制TXA2的产生，抗血小板的凝集，从而起到抗血栓的作用。但它在抑制TXA2产生的同时，也逐渐抑制具有舒张血管良好作用的PGI2的生成，而且还会产生消化系统的副作用及有关禁忌。
②.有活动性消化性溃疡病的人、患有体质性或后天性出血性疾病的人、高血压控制得不好的人、患有糖尿病且合并有视网膜出血的人，均不应服用阿司匹林。
③.患者在服用该药期间，还应注意该药引起的不良反应，如胃内不适、胃痛、鼻出血、齿龈出血、紫癜、荨麻疹、哮喘等。
④.有依赖性，长期使用会增加患者出血性风险，且不能双向调节血压，不适宜低血压患者。
⑤.没有根治的方法，停药后会立即复发。
现有技术中其它类似药物治疗高血脂存在以下不足：
①.副作用大，有泛酸、胃内不适、轻泻等副反应，胃酸过多或有溃疡病者宜慎用。
②.会引起肝功能损害，部分药物可使血糖增高。
③.只能控制在正常范围内，无法完全治愈。
其它采用深海鱼油、海狗油、海豹油为主要原料的非药物产品也存在以下不足：
①.来自于动物脂肪，富含胆固醇，长期摄入会造成人体内胆固醇增高，增加患冠心病的风险；
②.含量较低。主要成分：EPA和DHA，总含量相对比较低，仅含30%左右；
③.其活性物质比例已经固定，人体被动吸收。由于其直接含有EPA和DHA、不需要人体转化，人体是被动吸收，但是每个人所需EPA、DHA的量是不同的，而且难以掌握和判断所需的确定量，长期直接补充EPA、DHA时，会干扰人体本身固有的代谢；
④.易氧化，有鱼腥味，口感不好；
⑤.吸收率低。
⑥.非可持续性资源
鱼油的供给量将远远小于需求量,未来鱼油市场面临资源短缺的风险；
⑦.重金属污染比较严重，尤其汞污染严重,多种深海鱼如旗鱼和金枪鱼很有可能含甲基汞。
近年来许多医院、学者采用“换血”疗法治疗心脑血管，即采用血液换出等容量血浆的稀释疗法治疗急性期脑梗塞、高血脂等，收到了较为满意的疗效。该疗法就是抽出定量的全血，输入等量的血浆，其目的就是降低红细胞压积和血浆中大分子物质。对于高血脂患者，减少了体内一部分粘稠的血液，再通过正常的饮水，填充了血容量，使血液自然稀释，血脂就会随着下降，也就减轻了动脉硬化的隐患。有报道86%高血压患者，经血浆交换后，动脉压下降20%以上，其效果持续3～10个月；而对于高血脂患者，其效果持续3～6个月。但也存在很多问题：1.费用高，一般要上万元一次；2.风险大，血桨输入的安全性存在风险；3.持续时间短，一般持续3～10个月；4.治标不治本，不能从根本上解决心脑血管问题，持续3～10个月后又反弹了。
综上所述，血压和血脂就如同血液的“刹车”和“油门”。只降血压不降血脂，血液流动又将不断缓慢，血脂就会像洪水中的泥沙一样越聚越多，极易引起动脉硬化和脑血栓。只降血脂、不降血压，血液就会像没有阻力的洪水一样四处冲撞乱窜，极易造成脑溢血和冠心病；总体来看，用西药同时降压降脂，不但无法两全其美，反而会互相抵消疗效，还有许多的副作用。目前的药物治疗只是治标不治本，没有从源头上解决问题，故现有技术中高血压没有根治的方法，停药后会立即复发；而高血脂也只能控制在正常范围内，无法完全治愈。
发明内容
为了解决现有技术中存在的上述问题，本发明的目的是提供一种以紫苏油为主要原料精制而成，在人体内经过多种酶的转化后生成的代谢产物可以扩张血管、增强血管弹性、能使血浆中的中性脂肪（胆固醇、甘油三酯）下降的降血脂胶囊；其用于降血压和降血脂的疗效显著且无任何毒副作用。
为实现上述目的，本发明采用的技术方案为：一种降血脂胶囊包含α-亚麻酸、亚油酸和油酸；所述α-亚麻酸与亚油酸的质量比为4.377±0.1；所述α-亚麻酸与油酸的质量比为：4.096±0.1。
优选的技术方案，所述α-亚麻酸与亚油酸的质量比为4.377；所述α-亚麻酸与油酸的质量比为：4.096。
进一步的优选方案，所述α-亚麻酸从紫苏油中提取而得。
更进一步的优选方案，所述亚油酸从紫苏油中提取而得。
所述油酸从紫苏油中提取而得。
本发明相对于现有技术的有益效果为：本发明以紫苏油以主要原料精制而成，在人体内通过多种酶的转化能自动代谢生成：EPA、DPA、DHA等多种对人体有益的活性物质。
同时，本发明的降血脂胶囊还具有以下优点：
⒈营养丰富，补充全面。（本发明以紫苏油为主要原料，富含多种对人体有益的营养物质，主要成分：α-亚麻酸是ω-3系必需脂肪酸的母体，天然含量高达62.5%以上，α-亚麻酸与亚油酸含量比例高达4:1以上，科学合理，营养全面，有效避免药物的多种副作用和不足。）
⒉能同时调节血脂，调节血压，双向调节，不反弹。
⒊其活性物质比例科学、合理，吸收率大大提高。
⒋食用安全性高，不含对人体有害的胆固醇，以及过量服用会产生干扰代谢的副作用，且其过氧化值远低于鱼油等同类产品。
⒌不含EPA，在多种酶的作用下，根据人体需要主动转化吸收，不会干扰人体本身固有的代谢，充分体现人体差异，从而更好发挥效用。
⒍无重金属污染。
⒎无异味而且资源丰富。
⒏不容易氧化、稳定性好。
⒐软胶囊剂型，便于携带和服用。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了，下面结合具体实施方式，对本发明进一步详细说明。应该理解，这些描述只是示例性的，而并非要限制本发明的范围。此外，在以下说明中，省略了对公知结构和技术的描述，以避免不必要地混淆本发明的概念。
实施例1，本发明一种降血脂胶囊包含α-亚麻酸319.5mg、亚油酸73mg和油酸78mg；所述α-亚麻酸、亚油酸和油酸均来自于紫苏油。本胶囊还可以含有棕榈酸、硬脂酸、Vc、Ve、β-胡萝卜素、双萜、呋喃糖醛、花色苷、钙、铁、钾等。
本发明的胶囊具有以下优点：
本发明是以紫苏油以主要原料精制而成，在人体内通过多种酶的转化能自动代谢生成：EPA、DPA、DHA等多种对人体有益的活性物质。
①.本发明产品降血压的机制主要是通过影响前列腺素生成来实现的，其代谢产物可以扩张血管，增强血管弹性，能使血浆中的中性脂肪（胆固醇、甘油三酯）下降，这些综合到一起呈现血压下降作用。服用本发明产品既疗效显著，又无任何副作用。
②.本发明产品能够降低低密度脂蛋白在血液中含量，使大脑及心脏得到有效保护，其通过前列腺素的降脂途径具有全项降脂作用。
③.本发明产品在降低血浆总胆固醇的同时，不产生胆固醇在肝脏中累积，对人体更有益处。
④.纯植物提取，费用低
⑤.无不良反应，安全，高效，无痛苦。
⑥.因其能修复血液正常流变性，故持续时间长，不反弹。
⑦.无异味而且资源丰富、
⑧.在人体内能够主动吸收转化、活性物质比例科学合理，吸收率高。
⑨.不含胆固醇，且能降低胆固醇。克服了药物治疗所带来的毒副反应及伤害的不可逆性，并且弥补了药物和海洋制品的多项不足。
应当理解的是，本发明的上述具体实施方式仅仅用于示例性说明或解释本发明的原理，而不构成对本发明的限制。因此，在不偏离本发明的精神和范围的情况下所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。此外，本发明所附权利要求旨在涵盖落入所附权利要求范围和边界、或者这种范围和边界的等同形式内的全部变化和修改例。
Claims (5)
1.一种降血脂胶囊,其特征在于，所述胶囊包含α-亚麻酸、亚油酸和油酸；所述α-亚麻酸与亚油酸的质量比为4.377±0.1；所述α-亚麻酸与油酸的质量比为：4.096±0.1。
2.根据权利要求1所述的一种降血脂胶囊,其特征在于，所述α-亚麻酸与亚油酸的质量比为4.377；所述α-亚麻酸与油酸的质量比为：4.096。
3.根据权利要求1所述的一种降血脂胶囊,其特征在于，所述α-亚麻酸从紫苏油中提取而得。
4.根据权利要求1所述的一种降血脂胶囊,其特征在于，所述亚油酸从紫苏油中提取而得。
5.根据权利要求1所述的一种降血脂胶囊,其特征在于，所述油酸从紫苏油中提取而得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510039883.1A CN104814948A (zh) | 2015-01-27 | 2015-01-27 | 一种降血脂胶囊 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510039883.1A CN104814948A (zh) | 2015-01-27 | 2015-01-27 | 一种降血脂胶囊 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104814948A true CN104814948A (zh) | 2015-08-05 |
Family
ID=53725597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510039883.1A Pending CN104814948A (zh) | 2015-01-27 | 2015-01-27 | 一种降血脂胶囊 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104814948A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116056694A (zh) * | 2020-08-03 | 2023-05-02 | 富尔玛株式会社 | 消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 |
-
2015
- 2015-01-27 CN CN201510039883.1A patent/CN104814948A/zh active Pending
Non-Patent Citations (5)
| Title |
|---|
| 刘大川: "紫苏油及其营养价值", 《粮油加工与食品机械》 * |
| 徐冰冰等: "油用紫苏籽的综合利用", 《农业机械》 * |
| 杨静等: "α-亚麻酸的研究进展", 《农业工程》 * |
| 辛丹丹等: "国内外降脂药物的研究进展", 《内蒙古中医药》 * |
| 郭效祥: "《健康零距离：实用保健知识读本》", 30 September 2008, 黄河出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116056694A (zh) * | 2020-08-03 | 2023-05-02 | 富尔玛株式会社 | 消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Omega-3 fatty acids for cardioprotection | |
| EP1699449B1 (en) | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof | |
| NZ523138A (en) | Vitamin K and essential fatty acids | |
| Shahidi | Omega-3 fatty acids and marine oils in cardiovascular and general health: A critical overview of controversies and realities | |
| EA017496B1 (ru) | Композиция для регулирования метаболизма липидов | |
| Sawazaki et al. | The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study | |
| Asif | Chemical characteristics and nutritional potentials of unsaturated fatty acids | |
| US20160008300A1 (en) | Compositions and Methods for Nutritional Supplementation | |
| Harrison et al. | The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction | |
| Banning | The role of omega-3-fatty acids in the prevention of cardiac events | |
| Kandasamy et al. | The role of omega-3 fatty acids in cardiovascular disease, hypertriglyceridaemia and diabetes mellitus | |
| JP2016533716A (ja) | ステアリドン酸及びオリーブ油を含む食用の脂質組成物 | |
| CN108969540A (zh) | 一种用于防治骨关节炎的组合物及其制备方法和应用 | |
| CN104814948A (zh) | 一种降血脂胶囊 | |
| JP6450317B2 (ja) | Ｄｈａ及びｅｐａを含む軟カプセル | |
| CN101194913A (zh) | 治疗血脂偏高的天然海豹油浓缩生物制剂及其制备工艺 | |
| CN109527579A (zh) | 一种奇亚籽油制品及其制备方法和该奇亚籽油制品的应用 | |
| US20170065660A1 (en) | Nutraceutical composition and method of use thereof | |
| AHMAD et al. | A comparative study of antioxidant vitamins and simvastatin in hypercholesterolimic rabbits | |
| CN102771794A (zh) | 一种沙棘油维生素ec软胶囊 | |
| Nieves et al. | A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes | |
| CA2800438C (en) | Full spectrum fatty acid nutritional supplement | |
| CN101147736A (zh) | 一种降脂、降胆固醇组合物 | |
| Leyva et al. | Medicinal use of hempseeds (Cannabis sativa L.): effects on platelet aggregation | |
| CN110139645A (zh) | 用于预防和/或治疗恶病质的ω-3脂肪酸组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150805 |